PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free injection therapy (NFIT) systems, today announced the utilization of the Biojector® 2000 in Vical Inc.’s Phase 1 testing of its Vaxfectin™ formulated plasmid DNA (pDNA) pandemic influenza vaccine, placing Bioject at the forefront of ongoing influenza vaccine research.
